Level B· Emerging clinical evidence with positive signalsClinical TrialPubMed

Human adipose derived stroma/stem cells grow in serum-free medium as floating spheres.

Dromard C., Bourin P., André M., De Barros S., Casteilla L., Planat-Benard V.

Clinical Trial, published in Exp Cell Res (2011) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Exp Cell Res (2011)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
21255567
DOI
10.1016/j.yexcr.2011.01.001

Abstract (original English)

With the goal of obtaining clinically safe human adipose-derived stroma/stem cells (ASC) and eliminating the use of serum, we have developed a new culture system that allows the expansion of ASC as spheres in a defined medium. These spheres can be passaged several times. They are not only aggregated cells but rather originate from single cells as clonal spheres can be obtained after seeding at very low density and reform clonal spheres after dissociation. These spheres can also revert to monolayer growth when plated in medium containing human plasma and even generate fibroblast-like colonies (CFU-f). Under several differentiation-specific media, spheres-derived ASC maintain their capacity to differentiate into osteoblasts, endothelial cells and adipocytes. These results indicate that human ASC can be maintained in a serum-free 3D culture system, which is of great interest for the expansion in bioreactors of autologous ASC and their use in clinical trials.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
AdipocytesAdipose TissueCell Culture TechniquesCell DifferentiationCell LineageCulture Media, Serum-FreeFlow CytometryHumansMesenchymal Stem CellsReverse Transcriptase Polymerase Chain Reaction

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.